4-(2-吡啶基氧基)苯磺酰氯 | 192329-94-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(2-吡啶基氧基)苯磺酰氯
• 中文别名: 4-(2-吡啶氧)基苯磺酰氯；4-(吡啶-2-基氧基)苯-1-磺酰氯
• 英文名称: 4-(Pyrid-2-yl)oxybenzenesulfonyl chloride
• 英文别名: 4-(pyridin-2-yloxy)-benzenesulfonyl chloride；4-(Pyridin-2-yloxy)benzene-1-sulfonyl chloride；4-pyridin-2-yloxybenzenesulfonyl chloride
• CAS: 192329-94-5
• 化学式: C₁₁H₈ClNO₃S
• 分子量: 269.708
• InChiKey: CXLPHVTZYYDWQX-UHFFFAOYSA-N

物化性质

• 熔点：
  158 °C
• 沸点：
  392.1±22.0 °C(Predicted)
• 密度：
  1.420±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-吡啶基氧基)苯磺酰氯 、 3-(R)-amino-1-benzyloxy-1,3,4,7-tetrahydro-azepin-2-one 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 120.0h， 生成
  参考文献：
  名称：

  Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy

  摘要：

  The discovery of potent N-hydroxyl caprolactam matrix metalloproteinase (MMP) inhibitors (6) based on the natural product Cobactin-T (2) is described. The synthetic method, which utilizes the ring closing metathesis reaction, is compatible to provide complementary (R) and (S) enantiomers. These compounds tested against MMP-2 and 9, show that the R stereochemistry (i.e., 16), which is opposite for that found in the natural product Cobactin-T is >1000-fold more active with IC(50) values of 0.2-0.6 nM against both enzymes. The variation in the incorporation of the sulfonamide enzyme recognition element (Ar(2)XAr(1)SO(2)N(R(1)), 6), along with alterations in the RCM/double bond chemistry (R(2)) provided a series of sub nanomolar MMP inhibitors. For example, compounds 16 and 34 were found to be the most potent with IC(50) values against MMP-2 and MMP-9 found to be between 0.2 and 0.6 nM with 34 being the most potent compound discovered (MMP-2 IC(50) = 0.39 nM and MMP-9 IC(50) = 0.22 nM). Compounds 16 and 34 showed acceptable drug-like properties in vivo with compound 34 showing oral bioavailability. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.068
• 作为产物：
  描述：

  2-苯氧基吡啶 在 氯磺酸 作用下， 以 氯仿 为溶剂， 以56%的产率得到4-(2-吡啶基氧基)苯磺酰氯
  参考文献：
  名称：

  [EN] COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY
  [FR] COMPOSES A ACTIVITE ANTAGONISTE DE PGD2

  摘要：

  通式（I）的化合物；其中R1、R2、R3和R4独立地是氢、卤素、-C1-C6烷基、-O(C1-C6烷基)、-C1-C6烷基(C3-C7环烷基)、-CON(R9)2、-SOR9、-S02R9、-S02N(R9)2、-N(R9)2、-NR9OR9、-C02R9、COR9、-SR9、-OH、-N02或-CN；每个R9独立地是氢或C1-C6烷基；R5和R6独立地是氢或C1-C6烷基，或者与它们连接的碳原子一起形成一个C3-C7环烷基基团；R7是氢或C1-C6烷基；R8是C1-C6烷基、C2-C6烯基、C2-C6炔基或芳香基，其中任何一个可以选择地被一个或多个卤素、-SOR13、-S02R13、-R14、-OR14、-CON(R14)2、-SOR14、-S02R14、-S02N(R14)、-SO2N(R14)2、-N(R14)2、NR14COR14、-CO2R14、COR14、-SR14、-N02或-CN的取代基取代；其中R13是一个含有5至7个成员的杂环；每个R14独立地是氢、烷基或芳基，芳基可以选择地被-R9、-OR9、-CON(R9)2、-SOR9、-S02R9、-S02N(R9)2、-N(R9)2、NR9COR9、-C02R9、-COR9、-SR9、卤素、-N02或-CN取代；其中R9如上所定义；但是当R1、R3和R4是氢且R2是氢、卤素或-O(C1-C6)烷基时，R8不是未取代的苯基或被卤素、C1-C6烷基、-O(C1-C6)烷基、-S(C1-C6)烷基或-CO(C1-C6)烷基取代的苯基；或者其药学上可接受的盐、水合物、溶剂合物或前药在治疗过敏性疾病，如哮喘、过敏性鼻炎和特应性皮炎中有用。

  公开号：

  WO2005040112A1

文献信息

• Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06500948B1

  公开（公告）日：2002-12-31

  The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  这项发明涉及以下式子的化合物： 其中：Z为O或S；V为二价基团，与C*和N一起形成具有六个环原子的环，其中除C*和N之外的每个环原子独立地未取代或被适当取代基取代，且其中至少一个其他环原子为从O、N和S中选择的杂原子，其余为碳原子；Ar为芳基或杂芳基；以及其药学上可接受的前药、盐和溶剂化合物。 该发明还涉及这些化合物的药学上可接受的前药、盐和溶剂。该发明还涉及通过给予式I的化合物或其前药、盐或溶剂来抑制金属蛋白酶活性的方法。该发明还涉及包含这些化合物、前药、盐和溶剂的有效量的药物组合物。该发明还涉及用于制备这些化合物、前药、盐和溶剂的方法和中间体。
• Metalloproteinase inhibitors and intermediates useful for their
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06153757A1

  公开（公告）日：2000-11-28

  The invention relates to compounds of formula (1) ##STR1## wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  该发明涉及式（1）的化合物##STR1##其中：Z为O或S；V为与C*和N一起形成具有六个环原子的环的二价基团，其中除C*和N之外的每个环原子独立地未取代或被适当取代基取代，且所述其他环原子中至少有一个是从O、N和S中选择的杂原子，其余为碳原子；Ar为芳基或杂芳基团；以及其药学上可接受的前药、盐和溶剂化合物。该发明还涉及这些化合物的药学上可接受的前药、盐和溶剂。该发明还涉及通过给予式（1）的化合物或其前药、盐或溶剂来抑制金属蛋白酶活性的方法。该发明还涉及包含这些化合物、前药、盐和溶剂的有效量的药物组合物。该发明还涉及用于制备这些化合物、前药、盐和溶剂的方法和中间体。
• Metalloproteinase inhibitors, pharmaceutical compositions containing
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US05985900A1

  公开（公告）日：1999-11-16

  Compounds of the formula I: ##STR1## wherein Y is O or S, Ar is an aryl group or a heteroaryl group, R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or --C(O)R.sub.1, wherein R.sub.1 is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, and X is --NH--OH or --OH. Pharmaceutically acceptable prodrugs, salts and solvates of these compounds. Methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. Pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates.

  公式I的化合物：##STR1## 其中Y是O或S，Ar是芳基团或杂芳基团，R是H，烷基团，环烷基团，杂环烷基团，芳基团，杂芳基团或--C(O)R.sub.1，其中R.sub.1是氢，烷基团，环烷基团，杂环烷基团，芳基团，杂芳基团或NR.sub.2 R.sub.3，其中R.sub.2和R.sub.3独立的是氢，烷基团，环烷基团，杂环烷基团，芳基团或杂芳基团，X是--NH--OH或--OH。这些化合物的药物可接受的的前药，盐和溶剂化物。通过管理公式I的化合物或前药，盐或溶剂化物抑制金属蛋白酶活性的方法。包含有效量的这些化合物，前药，盐和溶剂化物的药物组合物。
• SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS
  申请人：Hofmeister Armin

  公开号：US20070203118A1

  公开（公告）日：2007-08-30

  The present invention is directed to a compound of formula (I) wherein R 1 , R 2 , R 3 , R 4 , A, L and n are as defined herein, or a pharmacologically acceptable salt thereof, its pharmaceutical composition and it use as a MMP inhibitor.

  本发明涉及一种具有以下化学式(I)的化合物，其中R1、R2、R3、R4、A、L和n如本文所定义，或其药理学上可接受的盐，以及其药物组合物及其作为MMP抑制剂的用途。
• HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS
  申请人：Zhang Yue-Mei

  公开号：US20080103129A1

  公开（公告）日：2008-05-01

  This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

  这项发明提供了一种新颖的杂环衍生物基质金属蛋白酶抑制剂的化学式，以及包含同样化合物的药物组合物，用于治疗通过拮抗基质金属蛋白酶而改善的疾病。该发明还提供了使用即时药物组合物的治疗和预防方法。